Neurogene raises $200M in oversubscribed PIPE; funds into H2 2027

Neurogene Inc.

Gross proceeds of ~$200M from sale of 1.835M shares at $50/share and 2.165M pre-funded warrants at $49.999 each.
Participating investors include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital, Samsara BioCapital.
Proceeds expected to fund company into second half of 2027 and support NGN-401 registrational study and CMC scale-up.
Closing expected Nov 5, 2024; post-transaction shares outstanding ~21.0M (assuming full warrant exercise).
Company to host webcast Nov 11, 2024 to review Phase 1/2 interim data for NGN-401 Rett syndrome gene therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.